Adaptive Biotechnologies Launches Enhanced Assay Reports for Patients with CLL

Adaptive Biotechnologies launched an enhanced version of its clonoSEQ® B-cell Clonality report. It will now feature the immunoglobulin heavy chain variable gene mutation status for patients with chronic lymphocytic leukemia (CLL).

The clonoSEQ assay was approved by the U.S. Food and Drug Administration to detect and monitor minimal residual disease in the blood or bone marrow of patients with CLL.

For more information on the clonoSEQ assay and its enhancements, read the Adaptive Biotechnologies announcement.

Posted 10/19/2021

Upcoming Events

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington